NEW YORK, March 8, 2016 /PRNewswire/ -- The global colorectal cancer diagnostics and therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 1-5% during the forecast period of 2015-2020. The market is valued at USD 14,143 million, as per 2015.
The CRC pipeline is highly robust, with a number of potential drug candidates present across the various phases of clinical development. With nearly 400 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or as second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as promising immunotherapies and chemotherapy drug candidates. Along with these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.
The global colorectal cancer diagnostics and therapeutics market is segmented on the basis of:
Digital rectal examination
Fecal occult blood test
Surgery and radiation therapy
Rest of the world
Some of the key players of the market are Abbott diagnostics, Alere, Beckman coulter, clinical genomics, Companion DX, EDP Biotech, Epigenomics AG, Exact sciences, Genomic tree, Metabiomics, Oncocyte, Quest Diagnostics, Randox Laboratories, Siemens Healthcare etc.
Increase of pipeline colorectal cancer screening tests
Increasing consumer awareness
Cost of screening test
Read the full report: http://www.reportlinker.com/p03687625-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001